Discovery and structure-activity relationship of P 1-P 3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease

Journal of Medicinal Chemistry

Volumn 52, Issue 2, 2009, Pages 336-346

  Venkatraman, Srikanth ^a   Velazquez, Francisco ^a   Wu, Wanli ^a   Blackman, Melissa ^a   Chen, Kevin X ^a   Bogen, Stephane ^a   Nair, Latha ^a   Tong, Xiao ^a   Chase, Robert ^a   Hart, Andrea ^a   Agrawal, Sony ^a   Pichardo, John ^a   Prongay, Andrew ^a   Cheng, Kuo Chi ^a   Girijavallabhan, Viyyoor ^a   Piwinski, John ^a   Shih, Neng Yang ^a   Njoroge, F George ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[[[[[(4,4 DIMETHYL 2,6 DIOXO 1 PIPERIDINYL)METHYL] 2,2 DIMETHYLPROPYL]AMINO]CARBONYL]AMINO] OCTADECAHYDRO 17,17 DIMETHYL ALPHA,1,14 TRIOXO N (2 PROPENYL) 2H CYCLOPROPA[3,4]PYRROLO[1,2 ALPHA][1,4]]DIAZACYCLOHEXADECINE ACETAMIDE; ACETAMIDE DERIVATIVE; BOCEPREVIR; IMIDE; LEUKOCYTE ELASTASE; MACROCYCLIC COMPOUND; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 3 PROTEASE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENZYME; AMIDE; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CYCLIZATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HEPATITIS C VIRUS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; ELECTROSPRAY MASS SPECTROMETRY; HYDROGEN BOND; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; X RAY CRYSTALLOGRAPHY;

AMIDES; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HYDROGEN BONDING; MACROCYCLIC COMPOUNDS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PROTEASE INHIBITORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 60549101206     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800940u     Document Type: Article

References (54)

1. (a). Fact Sheet Number 164; World Health Organization: Geneva, Switzerland, October 2000.
2. (b). Wasley, A.; Alter, M. J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 2000, 20, 1-16.
3. (c). Brown, R. S., Jr.; Gaglio, P. J. Scope of worldwide hepatitis C problem. Liver Transplant. 2003, 9, S10-S13.
4. (a). McHutchison, J. G.; Gordon, S. C.; Schiff, E. R.; Shiffman, M. L.; Lee, W. M.; Rustgi, V. K.; Goodman, Z. D.; Ling, M.-H.; Cort, S.; Albrecht, J. K. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998, 339, 1485-1492.
5. (b). Davis, G. L.; Esteban-Mur, R.; Rustgi, V.; Hoefs, J.; Gordon, S. C.; Trepo, C.; Shiffman, M. L.; Zeuzem, S.; Craxi, A.; Ling, M.-H.; Albrecht, J. Interferon alpha-2b alone or in combination with ribavirin for treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 1998, 339, 1493-1499.
6. (c). Zeuzem, S.; Feinman, S. V.; Rasenack, J.; Heathcote, E. J.; Lai, M.-Y.; Gane, E.; O'Grady, J.; Reichen, J.; Diago, M.; Lin, A.; Hoffman, J.; Brunda, M. J. Peginterferon alpha-2a in patients with chronic hepatitis C. N. Engl. J. Med. 2000, 343, 1666-1172.
7. (d). Heathcote, E. J.; Shiffman, M. L.; Cooksley, W. G. E.; Dusheiko, G. M.; Lee, S. S.; Balart, L.; Reindollar, R.; Reddy, R. K.; Wright, T. L.; Lin, A.; Hoffman, J.; De Pamphilis, J. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 2000, 343, 1673-1680.
8. (e). Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; Rustgi, V. K.; Shiffman, M.; Reindollar, R.; Goodman, Z. D.; Koury, K.; Ling, M.-H.; Albrecht, J. K. (and International Hepatitis Interventional Therapy Group). Lancet 2001, 358, 958-965.
9. (a). Llinas-Brunet, M.; Bailey, M. D.; Bolger, G.; Brochu, C.; Faucher, A.-M.; Ferland, J. M.; Garneau, M.; Ghiro, E.; Gorys, V.; Grand- Maitre, C.; Halmos, T.; Lapeyre-Paquette, N.; Liard, F.; Poirier, M.; Rheaume, M.; Tsantrizos, Y. S.; Lamarre, D. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J. Med. Chem. 2004, 47, 1605-1608.
10. (b). Perni, R. B.; Farmer, L. J.; Cottrell, K. M.; Court, J. J.; Courtney, L. F.; Deininger, D. D.; Gates, C. A.; Harbeson, S. L.; Kim, J. L.; Lin, C.; Lin, K.; Luong, Y.-P.; Maxwell, J. P.; Murcko, M. A.; Pitlik, J.; Rao, B. G.; Schairer, W. C.; Tung, R. D.; Van Drie, J. H.; Wilson, K.; Thomson, J. A. Inhibitors of hepatitis C virus NS3 • 4A protease. Part 3: P2 proline variants. Bioorg. Med. Chem. Lett. 2004, 14, 1939-1942.
11. (c). Lamar, J.; Victor, F.; Snyder, N.; Johnson, R. B.; Wang, Q. M.; Glass, J. I.; Chen, S.-H. Novel P4 truncated tripeptidyl (i-ketoamides as HCV protease inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 263-266.
12. (d). Nizi, E.; Koch, U.; Ontoria, J. M.; Marchetti, A.; Narjes, F.; Malancona, S.; Matassa, V. G.; Gardelli, C. Capped dipeptide phenethylamide inhibitors of the HCV NS3 protease. Bioorg. Med. Chem. Lett. 2004, 14, 2151-2154.
13. (e). Priestley, E. S.; De Lucca, I.; Ghavimi, B.; Erickson-Viitanen, S.; Decicco, C. P. P1 phenethyl peptide boronic acid inhibitors of HCV NS3 protease. Bioorg. Med. Chem. Lett. 2002,12, 3199-3202.
14. (f). Han, W.; Hu, Z.; Jiang, X.; Decicco, C. P. α -Ketoamides, α -ketoesters and ( α-diketones as HCV NS3 protease inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 711-713.
15. (g). Zhang, R.; Durkin, J. P.; Windsor, W. T. Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg. Med. Chem. Lett. 2002, 12, 1005-1008.
16. (h). Bogen, S.; Saksena, A. K.; Arasappan, A.; Gu, H.; Njoroge, F. G.; Girijavallabhan, V.; Pichardo, J.; Butkiewicz, N.; Prongay, A.; Madison, V. Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2- P1 cyclopropyl alanine combination for improved potency. Bioorg. Med. Chem. Lett. 2005, 15, 4515-4519.
17. (i). Victor, F.; Lamar, J.; Snyder, N.; Yip, Y.; Guo, D.; Yumibe, N.; Johnson, R. B.; Wang, Q. M.; Glass, J. I.; Chen, S.-H. P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl α -ketoamide based HCV protease inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 257-261.
18. Kaito, M.; Watnabe, S.; Tsukiyama-Kohara, K.; Yamaguchi, K.; Kobayashi, Y.; Konishi, M.; Yokoi, M.; Ishida, S.; Suzuki, S.; Kohara, M. Hepatitis C virus particle detected by immunoelectron microscopic study. J. Gen. Virol. 1994, 75, 1755-1760.
19. (a). Bartenschlager, R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J. Viral Hepatitis 1999, 6, 165-181.
20. (b). Bartenschlager, R.; Ahlborn-Laake, L.; Mous, J.; Jacobsen, H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 1993, 67, 3835-3844.
21. (c). Reed, K. E.; Rice, C. M. Molecular Characterization of Hepatitis C Virus. In Hepatitis C Virus; Reesink, H. W., Ed.; Karger: Basel, Switzerland, 1998; pp 1-37.
22. (d). Lindenbach, B. D.; Rice, C. M. Unravelling hepatitis C virus replication from genome to function. Nature 2005436, 933-938.
23. (a). Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bos, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagace, L.; LaPlante, S. R.; Narjes, H.; Poupart, M.-A.; Rancourt, J.; Sentjens, R. E.; George, T. S.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C.-L.; Llinas-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 18, 6-189.
24. 2 bearing peptidyl [alpha]- ketoamide LY514962 as HCV protease inhibitor. Bioorg. Med. Chem. Lett. 2004, 14, 251-256.
25. (c). Dymock, B. W. Emerging therapies for hepatitis C infection. Emerging Drugs 2001, 6, 13-42.
26. (d). De Francesco, R.; Migliaccio, G. Nature 2005, 436, 953-960.
27. (e). Perni, R. B.; Almquist, S. J.; Byrn, R. A.; Chandorkar, G.; Chaturvedi, P. R.; Courtney, L. F.; Decker, C. J.; Dinehart, K.; Gates, C. A.; Harbeson, S. L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.; Luong, Y.P.; Rao, B. G.; Taylor, W. P.; Thomson, J. A.; Tung, R. D.; Wei, Y.; Kwong, A. D.; Lin, C. Preclinical profile of VX-950, a potent, selective, and orally, bioavailable inhibitor of hepatitis C virus NS3- 4A serine protease. Antimicrob. Agents Chemother. 2006, 50, 899-909.
28. (f). Robison, P.; de Kock, H.; Rosenquist, A.; Nilsson, M.; Salvador-Oden, L.; Lin, T.-I.; Roue, N.; Ivanov, V.; Wahling, H.; Wickstrom, K.; Hamelink, E.; Edlund, M.; Vrang, L.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Boutton, C.; Lenz, O.; Delouvroy, F.; Pille, G.; Surleraux, D.; Wigerinck, P.; Samuelsson, B.; Simmen, K. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg. Med. Chem. Lett. 2008, 18, 4853-4858.
29. (g). Liverton, N. J.; Holloway, M. K.; McCauley, J. A.; Rudd, M. T.; Butcher, J. W.; Carroll, S. S.; DiMuzio, J.; Fandozzi, C.; Gilbert, K. F.; Mao, S.-S.; McIntyre, C. J.; Nguyen, K. T.; Romano, J. J.; Stahlhut, M.; Wan, B.-L.; Olsen, D. B.; Vacca, J. P. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/ 4A protease. J. Am. Chem. Soc. 2008, 130, 4607-4609.
30. (h). Brazil, M. Antiviral drugs: macrocyclic inhibitor for hepatitis C. Nat. Rev. Drug Discovery 2003, 212, 945.
31. (a). Youwei, Y.; Ying, L.; Sanjeev, M.; Vinod, S.; James, L. C.; Mohinder, M.; Christian, S.; Licia, T.; Raffaele, D.; Lawrence, K. C.; Zhongguo, C. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci. 1998, 7, 837-847.
32. (b). Love, R. A.; Parge, H. E.; Wichersham, J. A.; Hostomsky, Z.; Habuka, N.; Moomaw, E. W.; Adachi, T.; Hostomska, Z. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996, 87, 331-342.
33. (c). Kim, J. L.; Morgenstern, K. A.; Griffith, J. P.; Dweyer, M. D.; Thomson, J. A.; Murcko, M. A.; Lin, C.; Caron, P. R. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 1998, 6, 89-100.
34. (d). Kwong, A. D.; Kim, J. L.; Rao, G.; Lipovsek, D.; Raybuck, S. A. Hepatitis C virus NS3/4A protease. Antiviral Res. 1998, 40, 1-18.
35. Venkatraman, S.; Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y.-T.; Lovey, R.; Hendrata, S.; Huang, Y.; Pan, W.; Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santhanam, B.; Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.; Liu, R.; Butkiewicz, N.; Chase, R.; Hart, A.; Agarwal, S.; Ingravallo, P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcolm, B.; Guo, Z.; Prongay, A.; Madision, B. L.; Cui, X.; Cheng, K.-C.; Hsieh, T. Y.; Brisson, J.-M.; Prelusky, D.; Kormacher, W.; White, R.; Bogonowich- Knipp, S.; Pavlovsky, A.; Prudence, B.; Saksena, A. K.; Ganguly, A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F. G. Discovery of (1R,5S)-N-[3-Amino-1- (cyclobutylmethyl)-2-3-dioxopropyl]-3-[2(S)- [[[(1,1-dimethylethyl)-amino] carbonyl]amio]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan- 2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable, hepatits C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem. 2006, 49, 6074-6086.
36. (a). Zhang, R.; Beyer, B. M.; Durkin, J.; Ingram, R.; Njoroge, F. G.; Windsor, W. T.; Malcolm, B. A. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal. Biochem. 1999, 270, 268-275.
37. (b). Morrison, J. F.; Walsh, C. T. The behavior and significance of slow binding enzyme inhibitors. Adv. Enzymol. 1988, 61, 201-301.
38. Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285, 110-113.
39. (a). Marchetti, A.; Ontoria, J. M.; Matassa, V. G. Synthesis of two novel cyclic biphenyl ether analogs of an inhibitor of HCV NS3 protease. Synlett 1999, 1000-1002.
40. (b). Tyndall, J. D. A.; Fairlie, D. P. Macrocyclic mimic the extended peptide conformation recognized by aspartic, serine, cysteine, and metallo proteases. Curr. Med. Chem. 2001, 8, 893-907.
41. (a). Venkatraman, S.; Njoroge, F. G. Macrocyclic Inhibitors of HCV NS3 protease; design and strucure activity relationship. Curr. Top. Med. Chem. 2007, 7, 1290-1301.
42. (b). Chen, K. X.; Njoroge, F. G.; Pichardo, J.; Prongay, A.; Butkiewicz, N.; Yao, N.; Madison, V.; Girijavallabhan, V. Potent 7-hydroxy-1,2,3,4- tetrahydroisoquinoline- 3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease. J. Med. Chem. 2006, 49, 546-574.
43. (c)Venkatraman, S.; Njoroge, F. G.; Girijavallabhan, V. M.; Madison, V. S.; Yao, N H.; Prongay, A. J.; Butkiewicz, N.; Pichardo, J. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis c NS3-4A protease using structure-based drug design. J. Med. Chem. 2005, 48, 5088-5091.
44. Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y.-T.; Lovey, R. G.; Venkatraman, S.; Pan, W.; Parekh, T.; Pike, R. E.; Ruan, S.; Liu, R.; Baroudy, B.; Agrawal, S.; Ingravallo, P.; Pichardo, J.; Prongay, A.; Brisson, J.-M.; Hsieh, T. Y.; Cheng, K.-C.; Kemp, S. J.; Levy, O. E.; Lim-Wilby, M.; Tamura, S. Y.; Saksena, A. K.; Girijavallabhan, V.; Njoroge, F. G. Discovery of SCH 446211(SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication NS3 serine. J. Med. Chem. 2006, 49, 2750-2757.
45. Velazquez, F.; Venkatraman, S.; Wu, W.; Blackman, M.; Prongay, A.; Girijavallabhan, V.; Shih, N.-Y.; Njoroge, F. G. Application of ring-closing metathesis for the synthesis of macrocyclic peptidomimetics as inhibitors of HCV NS3 protease. Org. Lett. 2007, 9, 3061-3064.
46. 2] and its reactions. Angew. Chem., Int. Ed. Engl. 1995, 34, 2039-2041.
47. (b). Trnka, T. M.; Grubbs, R. H. The Development of L2X2Ru=CHR Olefin Metathesis Catalysts: An Organometallic Success Story. Acc. Chem. Res. 2001, 34, 18-29.
48. (a). Burk, M. J. C2-symmetric bis(phospholanes) and their use in highly enantioselective hydrogenation reactions. J.Am.Chem.Soc. 1991,113, 8518-8519.
49. (b). Burk, M. J. Modular phospholane ligands in asymmetric catalysis. Acc. Chem. Res. 2000, 33, 363-372.
50. (a). Mamai, A.; Zhang, R.; Natarajan, A.; Madalengoitia, J. S. PolyL-proline type-II peptide mimics based on the 3-azabicyclo[3.1.0]hexane system. J. Org. Chem. 2001, 66, 455-460.
51. (b). Zhang, R.; Madalengoitia, J. S. Design, synthesis and evaluation of poly-L-proline type- II peptide mimics based on the 3-azabicyclo[3.1.0]hexane system. J. Org. Chem. 1999, 64, 330-331.
52. Carpino, L. A. HATU = O-(7-azabenzotriazoll-yl-l,l,3,3-tetramethyluronium hexafluorophosphate. J. Am. Chem. Soc. 1993, 115, 4397.
53. Dess, D. B.; Martin, J. C. A useful 12-I-5 triacetoxyperiodinane (the Dess-Martin periodinane) for the selective oxidation of primary or secondary alcohols and a variety of related 12-I-5 species. J. Am. Chem. Soc. 1991, 113, 7277-7287.
54. Rats were orally administered with 10 mg of compound in 0.4% HPMC. Blood was withdrawn periodically and pooled. AUC was calculated over a 0- 6 h period. JM800940U